ABSTRACT
Thrombus treatment and prevention can be regulated by a number of intravenous or subcutaneous drugs, as well as oral warfarin. Many therapies require laboratory monitoring for efficacy and for detection of dangerous sequelae, such as bleeding, thrombosis, or heparin induced thrombocytopenia.
Subject(s)
Fibrinolytic Agents/therapeutic use , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/blood , Fibrinolytic Agents/pharmacokinetics , Fibrinolytic Agents/pharmacology , Humans , Monitoring, Physiologic , Thrombosis/drug therapy , Thrombosis/prevention & control , United StatesSubject(s)
Blood Transfusion/standards , Safety Management/methods , Humans , Laboratories , United StatesABSTRACT
Therapy of coagulation disorders has evolved from early use of fresh whole blood and plasma, to sophisticated recombinant factor concentrates. Although current testing protocols and viral inactivation methods ensure that transfusion of components is safer than ever, the potential for new threats continually exists, e.g., West Nile virus. Effective therapy depends on treating the specific deficiency with the safest and most appropriate replacement product, in the proper dose.